Sinoway Industrial Co., Ltd.

Eptifibatide 188627-80-7 Eptifibatide 188627-80-7

Eptifibatide 188627-80-7
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Eptifibatide:

Name

Eptifibatide

CAS NO.

188627-80-7

Molecular Formula

C35H49N11O9S2

Molecular Weight

831.96

Grade Standard

Medicine grade  / 99% min / FDA / DMF

Package Size

1kg/bag; 5kg/tin; 25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Eptifibatide:

Eptifibatide is an antiplatelet agent of glycoprotein IIb / IIIa inhibitors. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the Southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of arginine-glycine-aspartate-mimetic and reversibly binds to platelets. The half-life of eptifibatide is short. This drug is the third inhibitor of GPIIb / IIIa, which has been widely found after the specific antibodies abciximab and non-peptide tirofiban entered the global market.

Indications
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

Related ANTI-CANCER drug:
1. Cytarabine (CAS #147-94-4)
2. Methotrexate oral.Injection grade (CAS #59-05-2)
3. Paclitaxel(CAS:33069-62-4)
4. Doxorubicin Hydrochloride/CAS:25316-40-9
5. Vinblastine sulfate (CAS # 143-67-9)
6. Vincristine Sulfate (CAS #2068-78-2)
7. Vinorelbine Ditartrate (CAS #125317-39-7)
8. Gemcitabine hydrochloride (CAS#122111-03-9)
9. Mesylate-AZD9291 (CAS #1421373-66-1)

  • Progesterone 57-83-0
    Basic information:Product Name: Progesterone Molecular Formula : C21H30O2Molecular Weight: 314.46CAS No.: 57-83-0Appearance: White crystalline powderSpecifications:USP37/EP8.3Usages :Threatened abortion, ... Progesterone 57-83-0
  • Lenvatinib 857890-39-2
    Basic information of LenvatinibNameLenvatinibAliasLenvatinib MesylateCAS NO.857890-39-2Molecular FormulaC21H19ClN4O4.CH4O3SQuality Standard EPGrade StandardMedicine grade / 99% minPackage Size25kg/dr... Lenvatinib 857890-39-2
  • Spironolactone 52-01-7
    Basic informationProduct Name: Spironolactone Molecular Formula : C24H32O4SMolecular Weight: 416.57CAS No.: 52-01-7Appearance: White powderSpecifications:EP8/USP38UsagesTreat for High blood pressureTreat ... Spironolactone 52-01-7
  • Betamethasone Dipropionate 5593-20-4
    Basic information:Product Name: Betamethasone DipropionateMolecular Formula : C28H37FO7Molecular Weight: 504.59CAS No.: 5593-20-4Appearance: White powderSpecifications:USP37Usages :Betamethasone Diporpion... Betamethasone Dipropionate 5593-20-4

MORE_DETAIL Eptifibatide 188627-80-7

Basic information of Eptifibatide:

Name

Eptifibatide

CAS NO.

188627-80-7

Molecular Formula

C35H49N11O9S2

Molecular Weight

831.96

Grade Standard

Medicine grade  / 99% min / FDA / DMF

Package Size

1kg/bag; 5kg/tin; 25kg/drum

Storage:

Keep in a well-closed container, protected from light and stored at a temperature of 2 to 8


Use of Eptifibatide:

Eptifibatide is an antiplatelet agent of glycoprotein IIb / IIIa inhibitors. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the Southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of arginine-glycine-aspartate-mimetic and reversibly binds to platelets. The half-life of eptifibatide is short. This drug is the third inhibitor of GPIIb / IIIa, which has been widely found after the specific antibodies abciximab and non-peptide tirofiban entered the global market.

Indications
Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).
The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Additionally, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide.
The drug should exclusively be used in hospitalized patients both because of the serious degree of patients' illness and because of the possible side-effects of eptifibatide.

Related ANTI-CANCER drug:
1. Cytarabine (CAS #147-94-4)
2. Methotrexate oral.Injection grade (CAS #59-05-2)
3. Paclitaxel(CAS:33069-62-4)
4. Doxorubicin Hydrochloride/CAS:25316-40-9
5. Vinblastine sulfate (CAS # 143-67-9)
6. Vincristine Sulfate (CAS #2068-78-2)
7. Vinorelbine Ditartrate (CAS #125317-39-7)
8. Gemcitabine hydrochloride (CAS#122111-03-9)
9. Mesylate-AZD9291 (CAS #1421373-66-1)
Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5853819
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//